InvestorsHub Logo
Followers 73
Posts 6212
Boards Moderated 0
Alias Born 05/01/2011

Re: Cupo post# 212948

Friday, 09/06/2019 12:26:04 PM

Friday, September 06, 2019 12:26:04 PM

Post# of 425940
The comment that got me the most worked up about this (from JT):

But without any biological activity from LDL, which is the conclusion that FDA reached after its review of our first Phase 3 study, the MARINE study. And is consistent with the FDA's review of the ANCHOR study will conclude that the results of the ANCHOR study were truthful and non-misleading as presented. I remind folks that the active ingredient in Vascepa, which is stable. Eicosapentaenoic acid was studied in the JELIS trial in Japan. And while that's a Japanese-only patient population and it was essentially hypothesis generating for purposes of what we're doing.

There was no mineral oil used in that study, so clearly it wasn't mineral oil that was driving a result. So those who have looked at this data, the closest have been comfortable that the benefit demonstrated in the REDUCE-IT study is a benefit being driven by Vascepa and not by mineral oil. I appreciate that there's always contrarian that having scientific discussions of these matters is healthy.



The people who have looked at the data the closest know the real deal here.

“The trick is in what one emphasizes. We either make ourselves miserable, or we make ourselves happy. The amount of work is the same.” Carlos Castaneda

Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AMRN News